🇺🇸 LLY — Eli Lilly and Company

Salud Compra
← Volver

Precio actual

1.417,99 USD

Máx. histórico

1.417,99

0 días

Split 2:1 del 16/10/1997

Caída desde máximo

En máximo

Rango 52 semanas

850,51 – 1.449,68

Variación hoy

+0,61%

Cierre anterior

1.409,38

Rango de hoy

1.401,59 – 1.445,96

Volumen hoy

3.622.682

Peor caída histórica

-68,26%

08/08/2000 → 05/03/2009

Recuperado en 2064 días

Volatilidad anualizada ⓘ

27,61%

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
46,02 (puede no estar actualizado)
Dividend yield
0,49% (puede no estar actualizado)
Precio objetivo analistas
1.442,09 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 18 horas
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,47%
Fecha de pago Importe por participación
14/08/2026 1,7300 USD
15/05/2026 1,7300 USD
13/02/2026 1,7300 USD
14/11/2025 1,5000 USD
15/08/2025 1,5000 USD
16/05/2025 1,5000 USD
14/02/2025 1,5000 USD
15/11/2024 1,3000 USD
15/08/2024 1,3000 USD
15/05/2024 1,3000 USD
14/02/2024 1,3000 USD
14/11/2023 1,1300 USD
14/08/2023 1,1300 USD
12/05/2023 1,1300 USD
14/02/2023 1,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/03/2002 75,65 77,65 74,55 77,50 +2,34% 4,10% 2.902.700
28/02/2002 77,44 77,90 75,73 75,73 -2,21% 2,80% 2.669.500
27/02/2002 76,50 77,71 76,20 77,44 +2,00% 1,97% 2.543.100
26/02/2002 75,83 76,56 75,25 75,92 -0,95% 1,73% 3.213.300
25/02/2002 77,08 77,99 76,39 76,65 -0,56% 2,08% 2.775.400
22/02/2002 76,15 77,44 76,15 77,08 +0,63% 1,69% 2.616.200
21/02/2002 76,83 77,49 76,60 76,60 -0,30% 1,16% 3.269.300
20/02/2002 75,69 76,99 75,27 76,83 +1,52% 2,27% 2.887.700
19/02/2002 76,39 76,39 75,44 75,68 -0,93% 1,24% 1.636.300
15/02/2002 76,87 77,05 76,00 76,39 -0,04% 1,37% 1.925.500
14/02/2002 76,12 77,29 75,65 76,42 +0,39% 2,15% 2.835.700
13/02/2002 76,09 76,36 75,25 76,12 +0,49% 1,46% 1.908.700
12/02/2002 74,87 76,22 74,67 75,75 +1,19% 2,07% 2.318.200
11/02/2002 72,96 75,47 72,90 74,86 +1,62% 3,52% 2.185.100
08/02/2002 72,41 73,71 72,15 73,67 +1,11% 2,15% 2.211.800
07/02/2002 73,80 73,89 72,25 72,86 -0,68% 2,22% 2.471.000
06/02/2002 73,78 74,75 73,25 73,36 -0,78% 2,03% 2.384.500
05/02/2002 73,05 74,55 73,05 73,94 +0,87% 2,05% 2.251.800
04/02/2002 74,79 75,23 72,89 73,30 -1,99% 3,13% 1.887.200
01/02/2002 74,85 75,20 74,28 74,79 -0,41% 1,23% 1.941.700
31/01/2002 74,10 75,10 73,20 75,10 +1,43% 2,56% 3.081.300
30/01/2002 73,10 74,40 73,00 74,04 +0,87% 1,92% 3.451.100
29/01/2002 74,45 74,85 72,91 73,40 -1,20% 2,61% 2.812.400
28/01/2002 75,05 75,15 74,02 74,29 -1,09% 1,51% 2.568.700
25/01/2002 74,20 75,59 74,00 75,11 +1,36% 2,14% 3.654.100
24/01/2002 75,00 75,01 73,10 74,10 -2,20% 2,55% 5.630.500
23/01/2002 75,99 76,69 75,45 75,77 -0,11% 1,63% 2.752.800
22/01/2002 74,41 75,85 74,41 75,85 +1,69% 1,94% 3.622.700
18/01/2002 75,05 75,75 74,26 74,59 -1,11% 1,99% 3.904.500
17/01/2002 76,20 76,28 75,01 75,43 -0,83% 1,67% 2.304.400